anaemia. On two occasions (at 22 and 25 months of age) the intravenous route was transiently switched to oral treatment at a daily dose of 600 mg/m² (24 mg/kg) given in four or six divided doses. Each time the symptomatic relapse occurred and was corrected when the intravenous route was resumed. Plasma concentrations of zidovudine were measured by high performance liquid chromatography. At 150 mg/m²/6 hours (24 mg/kg/day) given orally, the peak plasma concentration one hour after oral dosing was 800 ng/ml and the trough level was undetectable (limit of detection: 12.5 ng/ml); these levels were similar to those determined in our other HIV positive children, excluding a specific defect of zidovudine absorption in our patient. Steady state concentration was 534 ng/ml during continuous infusion.

Haemorrhagic shock encephalopathy or near miss sudden infant death syndrome?

EDITOR,—Des Bacon and Hall suggest that haemorrhagic shock encephalopathy syndrome (HSES) is probably a secondary phenomenon after a severe initial insult.1 We hypothesise that this syndrome may represent the result of acute onset, severe hyponatraemia as may occur in infants who suffer apparent life threatening events (ALTE).2 Many of the features of HSES are similar to those that occur in infants who have suffered ALTE or sudden infant death syndrome (SIDS): median age of 15 weeks, peak onset period at night, slight excess in winter months, mild prodromal illness, found hot and sweaty, and with postmortem pulmonary congestion.

Previous reports on changes after severe 'near miss' SIDS have also shown the presence of metabolic acidosis, cardiovascular instability, acute renal failure, ischaemic colitis and acute neurological dysfunction.3 Some of these infants also showed mild hepatic cellular dysfunction and hyponatraemia. It may be appropriate for infants who have recovered from HSES to be screened for abnormalities in oxygenation. However, as with SIDS, the dilemma is to identify patients at risk of this life threatening illness before symptoms develop.

REPORTING OF VACCINE ASSOCIATED MUMPS MENINGITIS

EDITOR.—Vaccine associated mumps meningitis was one of the conditions reportable to the British Paediatric Surveillance Unit (BPSU) between February 1990 and January 1992. During this two year period, 15 confirmed cases were reported.1 Eight reports were in children aged 12-24 months resident in England and Wales. Based on the BPSU study the estimated risk of vaccine associated mumps meningitis in this age group was 1.5 per 100 000 vaccinations given. However when the BPSU data was supplemented by laboratory reports, a much higher rate of approximately 10 per 100 000 vaccinations was observed (Dr E Miller, personal communication). This higher rate is consistent with observations in other countries.

We are interested to read in recent reports in children 'has of yet not been satisfactorily explained'.


Treatment of refractory ulcerative oesophagitis with omeprazole

EDITOR.—We read the paper of Dalzell et al with interest. They reported a complete resolution of ulcerative oesophagitis refractory to H2 blockers by omeprazole in a 7 year old boy.

We recently saw a 4 month old boy who was diagnosed endoscopically to have an ulcerative oesophagitis at the age of 2 months. A two month course of cisapride, cimetidine, and a mucosal protective agent (alginic acid), together with thickening of the feeds and positioning initially improved his symptoms of crying when drinking milk. While still taking this treatment, however, excessive crying during and after milk feeding had recurred. Urine analysis was normal. A semisolid diet had already been introduced without obvious benefit. Endoscopy revealed a marked distal oesophagitis. Omeprazole at 3.5 mg (0.5 mg/kg) once a day was given for a period of six weeks. During the first 48 hours of this treatment, the clinical symptoms disappeared spectacularly. Endoscopy five weeks later did not reveal any signs of oesophagitis.

In both cases, omeprazole at 3.5 mg/kg had produced unequivocal improvements in severe oesophagitis refractory to treatment with H2 receptor antagonists. Rare side effects such as myopathy, epidermal necrosis, and endocrine adverse effects have been described.4 In infants and children, however, there is lack of experience and cautious use is warranted. Our report is to our knowledge the first to describe a beneficial effect of omeprazole on refractory oesophagitis in a young infant. Like Dalzell et al we suggest that omeprazole should be considered as an alternative treatment for refractory oesophagitis resistant to traditional treatment.

PHILIPPE ALLIET
MARC RAES
PHILIPPE GILLES
MIEKE CALLEWAERT
ANDRE ZIMMERMANN
Vera Tessa Hospital, Department of Paediatrics, Stadionomwall 11, B-3500 Hasselt, Belgium


Recurrent parotitis

EDITOR.—We were interested to read that the cause of recurrent parotitis in children 'has of yet not been satisfactorily explained'.

Reporting of vaccine associated mumps meningitis.

N Begg

Arch Dis Child 1993 68: 526
doi: 10.1136/adc.68.4.526

Updated information and services can be found at:
http://adc.bmj.com/content/68/4/526.1.citation

These include:

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/